Kroniskt obstruktiv lungsjukdom, KOL – Sköld

The prevalence of chronic obstructive pulmonary disease (COPD) is increasing in most parts of the world including Sweden. The disease, treated or untreated, leads to a progressive loss of lung function over time. So far, no treatment modalities have been shown to restore lung function impairment.
COPD is primarily an inflammatory disease of the peripheral airways, characterized by infiltration of macrophages and T lymphocytes. Besides smoking cessation, no efficacious treatments currently exist neither to prevent the inflammatory progression of COPD nor the progressive decline in lung function. The inflammation-induced tissue damage and subsequent remodelling invariably lead to impaired lung function and subsequent morbidity and mortality. Treatments with inhaled glucocorticoids, which are used to maintain most asthma patients, are largely ineffective in COPD patients. In macrophages from control subjects and healthy smokers, the release of inflammatory mediators is inhibited by corticosteroids, while corticosteroids remain inefficacious in macrophages of COPD patients.
Our overall goal is to characterize and to explore mechanisms of inflammation and remodeling in COPD, in order to provide a rational basis for development of new treatment strategies.

 

Om du skulle vilja stödja detta forskningsområde kan du göra det via följande konton:

BG 628-4418
PG 514114-8
Ange: Magnus Sköld

Om du befinner dig utanför Sverige, vänligen använd följande information:

Bank: SEB, Stockholm, Sweden
Kontonummer: 5201-11 370 12
Iban-nummer: SE16 5000 0000 0520 1113 7012
Bic-kod (bankens elektroniska adress): ESSESESS
Kontoinnehavare: Stiftelsen Centrum för Molekylär Medicin
L8:05, Karolinska Universitetssjukhuset
171 76 Stockholm, Sweden

CMM Research Groups

NEUROGENETIK OCH PSYKIATRISKA SJUKDOMAR

GENETISKA SJUKDOMAR

INFLAMMATORISKA SJUKDOMAR

KARDIOVASKULÄRA OCH METABOLA SJUKDOMAR